Literature DB >> 1998952

Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice.

K Endo1, Y Igarashi, M Nisar, Q H Zhou, S Hakomori.   

Abstract

Sphingosine (SPN) has been claimed to be a negative modulator of transmembrane signaling through protein kinase C (PK-C) or some yet unidentified mechanism [for review see Y. A. Hannun and R. M. Bell, Science (Washington DC), 243: 500-507, 1989]. N,N-Dimethylsphingosine (DMS) was recently found to be a physiological cellular component and, in comparison to SPN, to show a stronger and stereospecific inhibitory effect on PK-C activity of A431 cells (for review see Y. Igarashi, Trends Glycosci. Glycotechnol., 2: 319-332, 1990; and S. Hakomori, J. Biol. Chem., 265: 18713-18716, 1990). (4E)-N,N,N-Trimethyl-D-erythro-sphingenine (TMS) is not detectable as a normal cellular component; however, it is expected to exhibit potent activity because of its quaternary ammonium ion structure, and in fact it showed much stronger inhibitory effect than DMS or SPN on PK-C activity (which plays an important role in cell growth regulation) in vitro. In view of these findings, we investigated the effects of SPN, DMS, and TMS on in vitro growth of various human carcinoma cell lines and on in vivo tumor growth in athymic nu/nu mice. Both DMS and TMS showed similar in vitro and in vivo growth inhibitory effects on tumor cells, despite the fact that TMS showed a much stronger inhibitory effect than DMS on PK-C activity of A431 cells. In contrast, SPN showed only a weak effect on in vitro cell growth and no effect on in vivo tumor growth. Tumor growth following s.c. inoculation of mice with human gastric carcinoma cell line MKN74 was inhibited in a dose-dependent manner by DMS, and tumor size was decreased after three or four consecutive daily injections of 0.5-mg doses of DMS or TMS. Increased tumor growth occurred after administration of these compounds was stopped; however, size of tumor remained significantly smaller than in groups treated with SPN or control saline. The effect of DMS or TMS on in vitro or in vivo MKN74 cell growth was stronger than that of 8-chloro-adenosine-cyclic 3':5'-monophosphate dihydrate, the most promising agent currently being used in clinical trials for inhibition of tumor growth by induction of differentiation. These results suggest that DMS or TMS could be useful anticancer agents through modification of transmembrane signaling related to cancer cell growth.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998952

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells.

Authors:  Andrew J Kennedy; Thomas P Mathews; Yugesh Kharel; Saundra D Field; Morgan L Moyer; James E East; Joseph D Houck; Kevin R Lynch; Timothy L Macdonald
Journal:  J Med Chem       Date:  2011-05-02       Impact factor: 7.446

2.  Activation of caspase-3-like proteases in apoptosis induced by sphingosine and other long-chain bases in Hep3B hepatoma cells.

Authors:  W C Hung; H C Chang; L Y Chuang
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

Review 3.  STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer.

Authors:  Andrew V Nguyen; Yuan-Yuan Wu; Elaine Y Lin
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

4.  Roles of sphingosine 1-phosphate on tumorigenesis.

Authors:  Yuan-Li Huang; Wei-Pang Huang; Hsinyu Lee
Journal:  World J Biol Chem       Date:  2011-02-26

5.  Ceramide signaling in cancer and stem cells.

Authors:  Erhard Bieberich
Journal:  Future Lipidol       Date:  2008-06

Review 6.  Targeting SphK1 as a new strategy against cancer.

Authors:  Dai Shida; Kazuaki Takabe; Dmitri Kapitonov; Sheldon Milstien; Sarah Spiegel
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

Review 7.  Structure and function of glycosphingolipids and sphingolipids: recollections and future trends.

Authors:  Sen-itiroh Hakomori
Journal:  Biochim Biophys Acta       Date:  2007-09-06

Review 8.  Sphingolipid therapy in myocardial ischemia-reperfusion injury.

Authors:  Susheel Gundewar; David J Lefer
Journal:  Biochim Biophys Acta       Date:  2007-09-06

9.  Sphingosine 1-phosphate, a specific endogenous signaling molecule controlling cell motility and tumor cell invasiveness.

Authors:  Y Sadahira; F Ruan; S Hakomori; Y Igarashi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

10.  Ceramide and N,N,N-Trimethylphytosphingosine-Iodide (TMP-I)-Based Lipid Nanoparticles for Cancer Therapy.

Authors:  Prabagar Balakrishnan; Chung Kil Song; Alexander Jahn; Hyun-Jong Cho
Journal:  Pharm Res       Date:  2015-09-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.